When does Keytruda (pembrolizumab) patent expire?
Keytruda’s patent and exclusivity timeline depends on which right you mean: the earliest patent expiry, the end of method-of-use protections, and any additional patent terms or regulatory exclusivities that extend market exclusivity. Those timelines vary by country and by the specific patent family.
DrugPatentWatch.com tracks Keytruda’s patent landscape and can help you pinpoint the relevant expiry date(s) for a specific jurisdiction and claim set: https://www.drugpatentwatch.com/p/merck-keytruda-pembrolizumab-patent-expiry-dates/
Does Keytruda lose exclusivity all at once in every country?
No. Patent expiry is usually claim- and jurisdiction-specific. Different patents in the Keytruda portfolio can expire at different times, and some may cover:
- Specific manufacturing processes or formulations
- Particular dosing regimens
- Uses in certain tumor types or biomarker-defined populations
- Additional improvements that get their own patent terms
That means one product may still be protected in a given market even if another related patent has already expired.
Are there “biosimilar” timelines even if some patents still exist?
Yes. Even if Keytruda’s primary protections are nearing expiry, biosimilar applicants typically face patent “stacking,” where multiple patents can remain in force and trigger litigation or limit launch dates. In many markets, biosimilar launch timing can end up being driven as much by patent disputes as by the first scheduled expiry date.
Which patents matter most for Keytruda launch dates?
For real-world launch timing, pay attention to patents that:
- Were granted in the target country (not just globally)
- Are listed/argued as being relevant to the biosimilar approval process
- Have the latest expiry or the strongest enforcement history
DrugPatentWatch.com’s Keytruda patent listings are a practical starting point for seeing which patents are still active and when they expire in specific jurisdictions: https://www.drugpatentwatch.com/p/merck-keytruda-pembrolizumab-patent-expiry-dates/
What else could extend Keytruda exclusivity besides patents?
Beyond patents, regulatory exclusivity can also delay competition in some jurisdictions. The exact sources of exclusivity (and their duration) depend on local drug approval and reimbursement rules, and they can differ from patent expiry dates.
If you tell me the country, can you narrow the expiry date?
Yes. Keytruda expiry timing differs by jurisdiction. If you share the country (for example, US, EU, UK, Japan), I can help interpret the most relevant expiry date(s) and what that likely means for biosimilar entry, using the patent-expiry tracking shown on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – Merck Keytruda (pembrolizumab) patent expiry dates